Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology

Research Focus Area

Peptides studied in Metabolic & Weight research

Metabolic & Weight is a peptide research focus area. PeptideHelper.org catalogues compounds studied for this area with evidence tier, regulatory status, mechanism, and dosing reference for each.

Peptides studied for Metabolic & Weight (19)

Ranked by evidence tier first, then editorial popularity. "Studied for" describes published research focus, not clinical recommendation.

  1. Tirzepatide , GIP/GLP-1 dual incretin agonist · FDA-Approved · Prescription · 468 citations
    Weight loss up to 20-22% (SURMOUNT) [3]; HbA1c reduction [1][2]; BP and lipid improvement; reduced risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk (Mounjaro label indication since 2026) [1]
  2. Semaglutide , GLP-1 receptor agonist · FDA-Approved · Prescription · 630 citations
    Weight loss ~15% (STEP) [3]; HbA1c reduction [1][2]; cardiovascular protection (SELECT) [4]; appetite control [3]
  3. Dulaglutide , GLP-1 receptor agonist · FDA-Approved · Prescription · 323 citations
    T2D glycemic control; modest weight loss; cardiovascular protection (REWIND)
  4. Liraglutide , GLP-1 receptor agonist · FDA-Approved · Prescription · 341 citations
    T2D glycemic control; weight loss ~5-10% (Saxenda); cardiovascular protection
  5. Orforglipron , Oral non-peptide GLP-1 agonist · FDA-Approved · Prescription · 219 citations
    Weight loss 11.2% at 72 weeks (ATTAIN-1, n=3,127) [16]; 11.1% and 9.6% at the 17.2 mg label maximum in the two registration trials, 9.0 and 7.1 points over placebo [15]; HbA1c reduction ~1.5 points in early type 2 diabetes (ACHIEVE-1, n=559) [17]; oral once daily
  6. Retatrutide , GIP/GLP-1/glucagon triple agonist · Phase 3 · Investigational · 233 citations
    Phase 2 weight loss ~24% at 48 weeks; strong lipid/metabolic effects; NAFLD reduction
  7. CagriSema , Amylin + GLP-1 combination · Phase 3 · Investigational · 130 citations
    Weight loss ~15-22% Phase 2/3; enhanced appetite control
  8. Mazdutide , GLP-1/glucagon dual agonist · Phase 3 (China) · Investigational · 139 citations
    Weight loss; glycemic control; hepatic fat reduction (Phase 2/3 China)
  9. Survodutide , GLP-1/glucagon dual agonist · Phase 3 · Investigational · 151 citations
    Weight loss ~19%; MASH/NAFLD resolution Phase 2
  10. AOD-9604 , hGH fragment; lipolytic · Phase 2b (mixed) · Research / Anecdotal · 42 citations
    Lipolysis stimulation; fat loss without IGF-1 rise; no glucose effects
  11. Cagrilintide , Long-acting amylin analog · Phase 2/3 · Investigational · 186 citations
    Appetite suppression; weight loss ~10% monotherapy; synergy with semaglutide
  12. Tesofensine , Triple monoamine reuptake inhibitor (non-peptide) · Phase 2/3 (mixed) · Research Chemical · 120 citations
    Weight loss ~10% Phase 2; appetite suppression
  13. Eloralintide , Amylin receptor agonist (investigational) · Phase 1/2 · Investigational · 42 citations
    Weight loss; appetite control (Phase 1/2)
  14. MOTS-C , Mitochondrial-derived peptide (MDP); metabolic regulator · Early Clinical + Animal Studies · Research · 213 citations
    Insulin sensitization; AMPK activation; metabolic and mitochondrial support
  15. 5-Amino-1MQ , NNMT inhibitor small molecule · Preclinical + Anecdotal · Research Chemical · 24 citations
    NNMT inhibition; raises NAD+/SAM; fat metabolism; anti-obesity in mice
  16. Pancragen , Khavinson short peptide bioregulator · Russian Research · Research · 22 citations
    Pancreatic beta-cell support; glucose metabolism (animal/early human)
  17. AICAR , AMPK activator nucleoside (non-peptide) · Clinical Trials (banned in sport) · Research Chemical · 238 citations
    AMPK activation; fat oxidation; endurance; exercise mimetic
  18. Adipotide , Pro-apoptotic hybrid peptide; experimental · Preclinical (Editor-Flagged Toxic) · Experimental · 77 citations
    Targeted adipose vasculature apoptosis; rapid fat loss in primate models
  19. SLU-PP-332 , ERR agonist small molecule (non-peptide) · Preclinical · Experimental · 76 citations
    Exercise mimetic; endurance increase in mice; fat loss

Frequently asked questions

What peptides are most studied for Metabolic & Weight?

On PeptideHelper.org, the top compounds in this area by evidence tier and popularity are: Tirzepatide, Semaglutide, Dulaglutide. The full ranked list is below.

Are any Metabolic & Weight peptides FDA-approved?

5 compounds in this area are FDA-approved: Tirzepatide, Semaglutide, Dulaglutide, Liraglutide, Orforglipron.

How are peptides for Metabolic & Weight ranked on PeptideHelper.org?

Compounds are ranked first by evidence tier (FDA-approved, then Phase 3, Phase 2, Phase 1, animal studies, anecdotal), then by editorial popularity rank within the same tier.

Open the PeptideHelper.org goal evaluator to filter by goal, evidence tier, and regulatory status interactively.

Loading interactive view…